Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from Italy
Based on 2,110 articles published since 2008
||||

These are the 2110 published articles about Parkinson Disease that originated from Italy during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

2 Guideline EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012

Sorbi, S / Hort, J / Erkinjuntti, T / Fladby, T / Gainotti, G / Gurvit, H / Nacmias, B / Pasquier, F / Popescu, B O / Rektorova, I / Religa, D / Rusina, R / Rossor, M / Schmidt, R / Stefanova, E / Warren, J D / Scheltens, P / Anonymous1560734. ·Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. sorbi@unifi.it ·Eur J Neurol · Pubmed #22891773.

ABSTRACT: BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.

3 Editorial The need for an extensive neuropsychological assessment for a reliable diagnosis of mild cognitive impairment in patients with Parkinson's disease. 2018

Daniele, A / Lacidogna, G. ·Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy. ·Eur J Neurol · Pubmed #29509993.

ABSTRACT: -- No abstract --

4 Editorial News on the journal Neurological Sciences in 2017. 2018

Di Donato, Ilaria / Federico, Antonio. ·Department of Medicine, Surgery and Neurosciences, Medical School, University of Siena, Viale Bracci 2, 53100, Siena, Italy. · Department of Medicine, Surgery and Neurosciences, Medical School, University of Siena, Viale Bracci 2, 53100, Siena, Italy. federico@unisi.it. ·Neurol Sci · Pubmed #29327225.

ABSTRACT: -- No abstract --

5 Editorial Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months? 2018

Daniele, A / Panza, F. ·Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy. · Geriatric Unit and Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy. · Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy. · Neurodegenerative Disease Unit, Department of Clinical Research in Neurology, University of Bari 'Aldo Moro', Azienda Ospedaliera 'Card. G. Panico', Tricase, Italy. ·Eur J Neurol · Pubmed #29215769.

ABSTRACT: -- No abstract --

6 Editorial Classifying tremor: Language matters. 2018

Albanese, Alberto. ·Department of Neurology, Humanitas Research Hospital, Rozzano, Milano, Italy. · Department of Neurology, Catholic University, Milano, Italy. ·Mov Disord · Pubmed #29193400.

ABSTRACT: -- No abstract --

7 Editorial In vivo evaluation of central cholinergic circuits in Parkinson's disease using transcranial magnetic stimulation. 2017

Nardone, Raffaele / Trinka, Eugen. ·Department of Neurology, Franz Tappeiner Hospital, Merano, Italy; Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria. Electronic address: raffaele.nardone@asbmeran-o.it. · Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria; Centre for Cognitive Neurosciences Salzburg, Salzburg, Austria; University for Medical Informatics and Health Technology, UMIT, Hall in Tirol, Austria. ·Clin Neurophysiol · Pubmed #28427894.

ABSTRACT: -- No abstract --

8 Editorial Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon? 2016

Colosimo, C / Bhidayasiri, R. ·Department of Neurology, Santa Maria University Hospital, Terni, Italy. carlo.colosimo@uniroma1.it. · Department of Medicine, Faculty of Medicine, Chulalongkorn Center of Excellence for Parkinson's Disease and Related Disorders, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. · Department of Rehabilitation Medicine, Juntendo University, Tokyo, Japan. ·Eur J Neurol · Pubmed #27611181.

ABSTRACT: -- No abstract --

9 Editorial Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis. 2016

Calabresi, Paolo / Standaert, David G / Chiasserini, Davide / Parnetti, Lucilla. ·Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy. · IRCCS Fondazione Santa Lucia, Rome, Italy. · Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. ·Mov Disord · Pubmed #27245116.

ABSTRACT: -- No abstract --

10 Editorial Editorial: Critical Analyses of Mechanism-Based Therapies Against Parkinson's Disease: Concepts and Perspectives. 2016

Bisaglia, Marco. ·Molecular Physiology and Biophysics Unit Department of Biology, University of Padova Via Ugo Bassi 58/B, 35121 Padova Italy. marco.bisaglia@unipd.it. ·Curr Neuropharmacol · Pubmed #26951093.

ABSTRACT: -- No abstract --

11 Editorial A new scale for prognostication in Parkinson disease: Of animals and men. 2016

Chiò, Adriano / Defazio, Giovanni. ·From the "Rita Levi Montalcini" Department of Neuroscience (A.C.), University of Torino · Azienda Università Ospedale Città della Salute e della Scienza (A.C.), Torino · and Department of Basic Medical Sciences, Neuroscience and Sense Organs (G.D.), "Aldo Moro" University of Bari, Italy. ·Neurology · Pubmed #26888990.

ABSTRACT: -- No abstract --

12 Editorial Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights. 2016

Kimber, T / Antonini, A. ·Neurology Unit, Royal Adelaide Hospital and Department of Medicine, University of Adelaide, North Terrace, Adelaide, SA, Australia. Thomas.Kimber@sa.gov.au. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. ·Eur J Neurol · Pubmed #26663039.

ABSTRACT: -- No abstract --

13 Editorial A community study outlines how to prevent Parkinson's disease motor complications in the clinic. 2016

Logroscino, G. ·Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy. giancarlo.logroscino@uniba.it, giancarlo.logroscino@neurol.uniba.it. · Unit of Neurodegenerative Diseases, Department of Clinical Research in Neurology, University of Bari 'Aldo Moro', at Pia Fondazione Cardinale G. Panico, Tricase, Lecce, Italy. giancarlo.logroscino@uniba.it, giancarlo.logroscino@neurol.uniba.it. ·Eur J Neurol · Pubmed #26177048.

ABSTRACT: -- No abstract --

14 Editorial In vivo selection of novel biotherapeutics. 2015

Ruozi, Giulia / Giacca, Mauro. ·Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. ·Oncotarget · Pubmed #26387130.

ABSTRACT: -- No abstract --

15 Editorial The olfactory side of Parkinson disease: Relevance for clinical practice. 2015

Rossi, Simone / Ulivelli, Monica. ·From the Unit of Neurology and Clinical Neurophysiology, Department of Medical Science, Surgical Science and Neuroscience, Policlinico Le Scotte, University of Siena, Italy. rossisimo@unisi.it. · From the Unit of Neurology and Clinical Neurophysiology, Department of Medical Science, Surgical Science and Neuroscience, Policlinico Le Scotte, University of Siena, Italy. ·Neurology · Pubmed #26354987.

ABSTRACT: -- No abstract --

16 Editorial GTP cyclohydrolase 1 mutations and Parkinson's disease: new insights beyond DOPA-responsive dystonia. 2015

Carecchio, Miryam / Schneider, Susanne A. ·Molecular Neurogentics Unit, C. Besta Institute, Milan, Italy. · Neurology Department, University of Kiel, Kiel, Germany. ·Mov Disord · Pubmed #26012785.

ABSTRACT: -- No abstract --

17 Editorial How much does sex matter in Parkinson disease? 2015

Picillo, Marina / Fasano, Alfonso. ·From the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease (M.P., A.F.), Toronto Western Hospital and Division of Neurology, University of Toronto, Canada · and the Centre for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery (M.P.), University of Salerno, Italy. ·Neurology · Pubmed #25925984.

ABSTRACT: -- No abstract --

18 Editorial MicroRNAs as biomarker of Parkinson disease? Small but mighty. 2015

Marz, Manja / Ferracin, Manuela / Klein, Christine. ·From the Department of Bioinformatics (M.M.), Faculty of Mathematics and Computer Science, Friedrich Schiller University of Jena, Germany · Department of Morphology, Surgery and Experimental Medicine (M.F.), and Laboratory for the Technologies of Advanced Therapies, University of Ferrara, Italy · and Institute of Neurogenetics (C.K.), University of Luebeck, Germany. ·Neurology · Pubmed #25596504.

ABSTRACT: -- No abstract --

19 Editorial Resting-state fMRI sheds light on neural substrates of cognitive decline in Parkinson disease. 2014

Shinotoh, Hitoshi / Tessitore, Alessandro. ·From Chiba Neurology Clinic (H.S.) · Molecular Imaging Center (H.S.), National Institute of Radiological Sciences, Chiba, Japan · and Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences (A.T.), Second University of Naples, Italy. ·Neurology · Pubmed #25355820.

ABSTRACT: -- No abstract --

20 Editorial β-Amyloid in CSF: a window into Parkinson disease dementia. 2014

Siderowf, Andrew / Logroscino, Giancarlo. ·From Avid Radiopharmaceuticals (A.S.), Philadelphia, PA · and University of Bari (G.L.), Italy. ·Neurology · Pubmed #24748673.

ABSTRACT: -- No abstract --

21 Editorial Novel perspectives for Parkinson's disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets. 2013

Spano, Pier Franco / Bellucci, Arianna. ·Department of Molecular and Translational Medicine National Institute of Neuroscience University of Brescia Brescia Italy. bellucci@med.unibs.it. ·CNS Neurol Disord Drug Targets · Pubmed #24040812.

ABSTRACT: -- No abstract --

22 Editorial Towards a deeper comprehension of relationships among cognitive, behavioral and psychiatric symptoms in Parkinson's disease. 2013

Trojano, Luigi / Santangelo, Gabriella / Conson, Massimiliano / Grossi, Dario. ·Neuropsychology Lab, Department of Psychology, Second University of Naples, Caserta, Italy. ·Behav Neurol · Pubmed #23242354.

ABSTRACT: -- No abstract --

23 Review α-Synuclein and Glia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System? 2019

Filippini, Alice / Gennarelli, Massimo / Russo, Isabella. ·Biology and Genetic Unit, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. · Genetics Unit, IRCCS Istituto Centro S. Giovanni di Dio, Fatebenefratelli, 25123, Brescia, Italy. · Biology and Genetic Unit, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. isabella.russo@unibs.it. ·Cell Mol Neurobiol · Pubmed #30637614.

ABSTRACT: Accumulation of α-synuclein (α-syn) species in dopaminergic neurons is one of the main hallmarks of Parkinson's disease (PD). Several factors have been associated with α-syn aggregation process, including an impairment of the proper protein degradation, which might drive the neurons toward an alternative and/or additional clearance mechanism that involves the release of undigested material from the cell. It has been reported that extracellular α-syn, released by stressed and/or degenerating neurons, might widely contribute to the neuronal toxicity and degeneration. Therefore, the uptake and clearance of misfolded/aggregated proteins is a key process to control extracellular deposition of α-syn aggregates, the spreading and progression of the disease. All the main brain cell types, neurons, astrocytes and microglia are able to internalize and degrade extracellular α-syn, however, glial cells appear to be the most efficient scavengers. Accumulating evidence indicates that the endocytosis of α-syn species might be conformation-sensitive, cell- and receptor-type specific, making the scenario highly complex. In this review, we will shed light on the different endocytosis mechanisms and receptors recruited for the uptake and clearance of pathological α-syn forms with a special focus on glial cells. Moreover, we will discuss how PD-related genes, in addition to α-syn itself, may alter the endo-lysosomal pathway causing an impairment of clearance, which, in turn, lead to accumulation of toxic species, dysfunctions of glia physiology and progression of the disease.

24 Review Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. 2019

Longhena, Francesca / Faustini, Gaia / Spillantini, Maria Grazia / Bellucci, Arianna. ·Division of Pharmacology, Department of molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. f.longhena@unibs.it. · Division of Pharmacology, Department of molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. g.faustini004@unibs.it. · Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK. mgs11@cam.ac.uk. · Division of Pharmacology, Department of molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. arianna.bellucci@unibs.it. · Laboratory for Preventive and Personalized Medicine, Department of molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. arianna.bellucci@unibs.it. ·Int J Mol Sci · Pubmed #30609739.

ABSTRACT: Alpha-synuclein (α-syn) is a small protein that, in neurons, localizes predominantly to presynaptic terminals. Due to elevated conformational plasticity, which can be affected by environmental factors, in addition to undergoing disorder-to-order transition upon interaction with different interactants, α-syn is counted among the intrinsically disordered proteins (IDPs) family. As with many other IDPs, α-syn is considered a hub protein. This function is particularly relevant at synaptic sites, where α-syn is abundant and interacts with many partners, such as monoamine transporters, cytoskeletal components, lipid membranes, chaperones and synaptic vesicles (SV)-associated proteins. These protein⁻protein and protein⁻lipid membrane interactions are crucial for synaptic functional homeostasis, and alterations in α-syn can cause disruption of this complex network, and thus a failure of the synaptic machinery. Alterations of the synaptic environment or post-translational modification of α-syn can induce its misfolding, resulting in the formation of oligomers or fibrillary aggregates. These α-syn species are thought to play a pathological role in neurodegenerative disorders with α-syn deposits such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), which are referred to as synucleinopathies. Here, we aim at revising the complex and promiscuous role of α-syn at synaptic terminals in order to decipher whether α-syn molecular interactants may influence its conformational state, contributing to its aggregation, or whether they are just affected by it.

25 Review Circadian Rhythm Abnormalities in Parkinson's Disease from Humans to Flies and Back. 2018

De Lazzari, Federica / Bisaglia, Marco / Zordan, Mauro Agostino / Sandrelli, Federica. ·Department of Biology, University of Padova, 35131 Padova, Italy. federica.delazzari@phd.unipd.it. · Department of Biology, University of Padova, 35131 Padova, Italy. marco.bisaglia@unipd.it. · Department of Biology, University of Padova, 35131 Padova, Italy. mauroagostino.zordan@unipd.it. · Cognitive Neuroscience Center, University of Padova, 35100 Padova, Italy. mauroagostino.zordan@unipd.it. · Department of Biology, University of Padova, 35131 Padova, Italy. federica.sandrelli@unipd.it. ·Int J Mol Sci · Pubmed #30563246.

ABSTRACT: Clinical and research studies have suggested a link between Parkinson's disease (PD) and alterations in the circadian clock.

Next